What are the efficacy and effects of erdafitinib? Treatment effectiveness for different cancer types

Erdafitinib is a targeted drug that is a tyrosine kinase inhibitor that mainly works by inhibiting the FGFR (fibroblast growth factor receptor) signaling pathway. It is particularly suitable for treating cancers carrying FGFR gene mutations, by targeting and inhibiting the receptors of these mutations, blocking the proliferation and growth of tumor cells and reducing tumor expansion. Erdafitinib is already approved for the treatment of metastatic urothelial carcinoma (UC) and has shown potential efficacy in other types of cancer.

First, erdafitinib has a significant therapeutic effect on metastatic urothelial carcinoma (UC). In clinical trials, erdafitinib has been shown to have good efficacy in patients with urothelial cancer who have been treated with at least one chemotherapy regimen and have FGFR2 or FGFR3 mutations. About 30% of patients experienced partial remission or stable tumor response after treatment, and the treatment was well tolerated. This makes erdafitinib an effective treatment option for some patients with refractory urothelial cancer.

Secondly, erdafitinib also shows certain efficacy for other types of cancer. For example, in diseases such as cholangiocarcinoma, non-small cell lung cancer (NSCLC), and bladder cancer, FGFR mutations are also a mechanism of tumor development. Studies have shown that erdafitinib can effectively inhibit the effects of FGFR gene mutations in these tumors, thereby slowing tumor growth and improving patients' quality of life. Although the application of erdafitinib in these cancers is still in the clinical trial stage, preliminary data indicate that it has certain therapeutic potential.
However, although erdafitinib has significant efficacy in cancer patients carrying FGFR mutations, its therapeutic effect is relatively poor in patients without FGFR mutations. Therefore, before using erdafitinib, patients need to confirm whether there are relevant FGFR mutations through genetic testing to ensure the accuracy and effectiveness of treatment.
Overall, erdafitinib is a promising targeted therapy that can significantly improve the therapeutic effect of patients with advanced or metastatic cancers with FGFR mutations.
Reference link: https://www.balversa.com/